Boryung

Boryung, a pharmaceutical preparation manufacturer headquartered in South Korea, reported total emissions of approximately 27,457,000 kg CO2e for 2023. This figure comprises Scope 2 emissions of about 343,000 kg CO2e and Scope 1 and 2 combined emissions of approximately 27,457,000 kg CO2e. In 2022, total emissions were approximately 27,499,000 kg CO2e, with Scope 2 emissions around 333,000 kg CO2e. The previous year, 2021, saw total emissions of approximately 24,857,000 kg CO2e, with Scope 2 emissions at about 299,000 kg CO2e.

For 2020, Boryung reported Scope 1 emissions of approximately 3,906,000 kg CO2e and Scope 2 emissions of approximately 22,623,000 kg CO2e, resulting in combined Scope 1 and 2 emissions of approximately 26,482,000 kg CO2e.

Boryung's disclosed emissions data primarily covers Scope 1 and Scope 2. While Scope 3 emissions, specifically purchased goods and services, are noted as missing data points, the company has not disclosed specific reduction targets or commitments to initiatives like the Science Based Targets initiative (SBTi) or RE100. The company's reporting indicates a focus on Scope 2 emissions for 2021-2023, with Scope 1 data only explicitly reported for 2020.